Abstract
Objectives
To evaluate the effect of locally advanced periocular basal cell carcinoma (POLA-BCC) on health-related quality of life (HRQoL) and the benefit of vismodegib treatment among participants in the Safety Events in Vismodegib (STEVIE) trial between 2011 and 2017.
Methods
The STEVIE trial was conducted in patients with BCC (all anatomic locations) who were treated with vismodegib in 28-day cycles. Patients completed the Skindex-16, a validated questionnaire for the analysis symptoms, emotions, and functioning, at baseline, on day 1 of cycle 2, on day 1 of cycle 7, and at the end-of-study visit. For the present study, data mining techniques were used to construct an ophthalmic database of the STEVIE study. Skindex-16 scores were compared among patients with POLA-BCC between baseline and follow-up and between patients with POLA-BCC and patients with locally advanced BCC on other sites of the head and face (controls).
Results
The cohort included 169 patients with POLA-BCC and 428 patients with non-periocular head BCC. Patients with POLA-BCC had a significantly worse overall functioning score at baseline than controls (p = 0.038) and a lower score specifically in activities of daily living (p = 0.001). At the last follow-up, patients with POLA-BCC showed significant improvement in scores for functioning (100%), symptoms (100%), and emotions (75%) relative to baseline.
Conclusions
Secondary analysis of the results of the STEVIE trial showed that the HRQoL of patients with POLA-BCC is significantly impaired and can be greatly improved with vismodegib treatment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–9. https://doi.org/10.1056/NEJMra044151.
Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151:976–81. https://doi.org/10.1001/jamadermatol.2015.1188.
Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743–54. https://doi.org/10.1038/nrc2503.
Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25:218–23. https://doi.org/10.1097/CCO.0b013e32835ff438.
Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–48. https://doi.org/10.1016/j.ejca.2017.08.022.
Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surgical Oncol Clin North Am. 2018;27:675–84. https://doi.org/10.1016/j.soc.2018.05.008.
Forsyth RJ. We have to talk about health-related quality of life. Arch Dis Child. 2018;103:913–4. https://doi.org/10.1136/archdischild-2018-314951.
Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res. 1996;5:191–4. https://doi.org/10.1007/bf00434740.
Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dreno B, et al. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. Eur J Dermatol. 2018;28:775–83. https://doi.org/10.1684/ejd.2018.3448.
Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthalmic Plast Reconstructive Surg. 2013;29:87–92. https://doi.org/10.1097/IOP.0b013e3182831bf3.
Nix NM, Burdine O, Walker M. Vismodegib: first-in-class hedgehog pathway inhibitor for metastatic or locally advanced basal cell carcinoma. J Adv Practitioner Oncol. 2014;5:294–6. https://doi.org/10.6004/jadpro.2014.5.4.7.
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16:729–36. https://doi.org/10.1016/S1470-2045(15)70198-1.
Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I. Outcomes of Vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial. JAMA Ophthalmol. 2020. https://doi.org/10.1001/jamaophthalmol.2020.1539.
Clarke A, Rumsey N, Collin JR, Wyn-Williams M. Psychosocial distress associated with disfiguring eye conditions. Eye. 2003;17:35–40. https://doi.org/10.1038/sj.eye.6700234.
Hamedani AG, VanderBeek BL, Willis AW. Blindness and visual impairment in the medicare population: disparities and association with hip fracture and neuropsychiatric outcomes. Ophthalmic Epidemiol. 2019;26:279–85. https://doi.org/10.1080/09286586.2019.1611879.
Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatologic Clin. 2012;30:231–6. https://doi.org/10.1016/j.det.2011.11.003.
Shingler SL, Garside J, Samanta K, Lear JT, Keohane S, Lloyd AJ. Utilities for advanced basal cell carcinoma. J Med Econ. 2013;16:777–83. https://doi.org/10.3111/13696998.2013.800822.
Steenrod AW, Smyth EN, Bush EN, Chang AL, Arron ST, Helfrich YR, et al. A qualitative comparison of symptoms and impact of varying stages of basal cell carcinoma. Dermatol Ther. 2015;5:183–99. https://doi.org/10.1007/s13555-015-0081-6.
Alon Kahana M. Vismodegib for basal cell carcinoma. In: Kanaga Rajan P, editor. AAO Daily 2019. 2019.
Durnian JM, Noonan CP, Marsh IB. The psychosocial effects of adult strabismus: a review. Br J Ophthalmol. 2011;95:450–3. https://doi.org/10.1136/bjo.2010.188425.
McKee S. Roche’s Erivedge no longer funded by the NHSPharmaTimes online. 2017.
Review P-COD. Final Reccomendation for Vismodegib (Erivedge) for Basal Cell Carcinoma pERC Meeting. January, 2013; Reconsideration Meeting: December 19, 2013.
Frampton JE, Basset-Seguin N. Vismodegib: a review in advanced basal cell carcinoma. Drugs. 2018;78:1145–56. https://doi.org/10.1007/s40265-018-0948-9.
Acknowledgements
We thank all the patients and their families, investigators, and research teams who participated in this study. F. Hoffman-La Roche Ltd, for providing the data from the STEVIE study for analysis.
Author information
Authors and Affiliations
Contributions
AG and AT acquired the data and drafted the manuscript. MB-I and EB analyzed the data and aided in interpreting the results. GBS and IY designed the current study and revised the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
This study was a secondary analysis of the STEVIE data and did not involve the recruitment of new participants. Therefore, institutional review board approval and patient consent were waived by our institutional protocol. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gershoni, A., Tiosano, A., Ben Ishai, M. et al. Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial. Eye 36, 407–413 (2022). https://doi.org/10.1038/s41433-021-01493-2
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-021-01493-2
